预约演示
更新于：2025-08-19
Scopolamine Butylbromide
丁溴东莨菪碱
更新于：2025-08-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1955-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H30BrNO4 |
InChIKeyHOZOZZFCZRXYEK-GSWUYBTGSA-M |
CAS号149-64-4 |
关联
97
项与 丁溴东莨菪碱 相关的临床试验NCT06398054
Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial
PACTR202502489216837
Effect of hyoscine -n-butylbromide on the duration of active phase of labour in term pregnancies: a randomized-controlled clinical trial.
PACTR202407560838827
Cervical ripening /Labour induction in postdate nulliparas; Comparative study of vaginal misoprostol versus vaginal misoprostol with rectal hyoscine-butylbromide
100 项与 丁溴东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的专利（医药）
登录后查看更多信息
929
项与 丁溴东莨菪碱 相关的文献（医药）2025-09-01Integrative Medicine Research
Efficacy of herbal medicine (Thatbunjob) in the treatment of foodborne illness: A placebo-controlled, randomized trial
Article
作者: Bhanthumkomol, Patommatat ; Eiamsitrakoon, Thanee ; Sakpakdeejaroen, Intouch ; Jaicharoensub, Jaiboonya ; Panthong, Sumalee
Background:
Foodborne illness (FI) causes 600 million cases and 420,000 deaths annually. Current treatments focus on rehydration and antispasmodic medications for managing dehydration and abdominal pain (AP). However, alternative therapies, especially those derived from natural ingredients, are needed. This study investigates the potential efficacy of herbal medicine,Thatbunjob as a complementary therapy for FI-related AP.
Methods:
A double-blind, randomized, placebo-controlled clinical trial assessed the efficacy of Thatbunjob in relieving AP in FI patients. A total of 114 patients, aged 18-60, with AP and diarrhea (≥3 episodes in 24 h), received either two 500 mg capsules of Thatbunjob or a placebo three times daily for three days. Both groups also received standard oral rehydration therapy. Primary outcomes included AP intensity using a visual analog scale (VAS) at 24 h, while secondary outcomes included pain at 48 and 72 h, responder rates, hyoscine butyl bromide usage, stool frequency, and adverse events.
Results:
The Thatbunjob group showed significantly greater reduction in AP compared to the placebo. VAS scores decreased from 5.69 to 2.95 at 24 h (P < 0.001), and pain relief persisted at 48 (1.43 vs. 3.05, P < 0.001) and 72 h (0.32 vs. 1.86, P < 0.001). Thatbunjob also reduced the need for hyoscine tablets and decreased stool frequency compared to placebo.
Conclusion:
This study demonstrates that Thatbunjob, when combined with standard rehydration therapy, effectively alleviates AP and reduces stool frequency in FI patients.
Trial registration:
Thai Clinical Trials Registry, TCTR20220823001.
2025-06-01British Journal of Pharmacology
Oral hyoscine butylbromide exerts spasmolytic effects in both gastrointestinal and urogenital tissues in rats
Article
作者: Lange, Robert ; Appelqvist, Terence ; Corsetti, Maura ; Jimenez, Marcel ; Traserra, Sara
Background and Purpose:
Hyoscine butylbromide (HBB) has a low oral (PO) bioavailability. Further, limited data on its activity on non‐gastrointestinal (GI) smooth muscle spasms after oral dosing are available, causing its effects beyond the GI tract to be questioned. This pharmacokinetic/pharmacodynamic (PK/PD) study, conducted using female rats, aimed to cover this gap.
Experimental Approach:
PK study: HBB and atropine (as a comparator agent) were administered PO and IV to rats, and concentrations in plasma and tissues (colon, uterus and urinary bladder; CUB) were measured. PD study 1: concentration–response curves of HBB and atropine (10−9–10−4 M) were obtained for carbachol‐induced (10−5 M) pre‐contracted tissues; PD study 2: CUB were pre‐incubated with HBB and atropine at maximum concentrations (Cmax) from PK studies and carbachol concentration–response curves (10−9–10−4 M) were obtained; PD study 3: HBB and atropine were administered PO and IV to rats as for PK study, CUB tissues were collected at 0.5 h (IV) and 4 h (PO), and carbachol concentration–response curves (10−9–10−4 M) obtained.
Key Results:
PO HBB showed higher Cmax in CUB tissues than in plasma. HBB and atropine reduced, concentration‐dependently, carbachol‐induced contractions in CUB tissues. PO HBB showed highest spasmolytic activity in colon (40%), followed by uterus (30%) and urinary bladder (10%).
Conclusion and Implications:
This is the first comparison of PO and IV HBB and atropine in GI and non‐GI tissues. Despite low bioavailability, PO HBB accumulated and exerted spasmolytic effects in tissues beyond the GI tract.
2025-05-01MAGNETIC RESONANCE IMAGING
Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission
Article
作者: Valentin, B ; Drewes, L ; Wittsack, H J ; Radtke, J P ; Antoch, G ; Albers, P ; Boschheidgen, M ; Ullrich, T ; Trappe, S ; Al-Monajjed, R ; Schimmöller, L
OBJECTIVE:
To investigate the use of deep learning (DL) T2-weighted turbo spin echo (TSE) imaging sequence with deep learning acceleration (T2DL) in prostate MRI regarding the necessity of hyoscine butylbromide (HBB) administration for high image quality.
METHODS:
One hundred twenty consecutive patients divided into four groups (30 for each group) were included in this study. All patients received a T2DL (version 2022/23) and a conventional T2 TSE (cT2) sequence on an implemented 3 T scanner and software system. Group A received cT2 with HBB compared to T2DL without HBB with a field of view (FOV) of 130 mm and group B with a FOV of 160 mm. Group C received both sequences with a FOV of 160 mm plus HBB and group D without HBB. Two radiologists independently evaluated all imaging datasets in a blinded reading regarding motion, sharpness, noise, and diagnostic confidence. Furthermore, we analyzed quantitative parameters by calculating edge rise distance (ERD), signal-to-noise-ratio (SNR), and contrast-to-noise-ratio (CNR). Friedman test was used for group comparisons.
RESULTS:
Baseline characteristics showed no significant differences between groups A-D. After HBB cT2 showed less motion artifacts, more sharpness, and a higher diagnostic confidence than T2DL, though DL sequences had significantly lower noise (p < 0.01). Quantitative analysis revealed higher SNR and CNR for T2DL sequences (p < 0.01), while edge rise distance (ERD) remained similar. Inter-reader agreement was good to excellent, with ICCs ranging from 0.84 to 0.93. T2DL acquisition time was significantly lower than for cT2.
CONCLUSIONS:
In our study, cT2 sequences with HBB showed superior image quality and diagnostic confidence while the T2DL sequence offer promising potential for reducing MRI acquisition times and performed better in quantitative measures like SNR and CNR. Additional studies are required to evaluate further adjusted and developed DL applications for prostate MRI on upcoming scanner generations and to assess tumor detection rates.
65
项与 丁溴东莨菪碱 相关的新闻（医药）2025-07-13
·信狐药迅
100 项与 丁溴东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃肠痉挛 | 澳大利亚 | 1991-09-26 | |
| 肾绞痛 | 澳大利亚 | 1991-09-26 | |
| 胆道痉挛 | 澳大利亚 | 1991-09-26 | |
| 晕动病 | 美国 | 1979-12-31 | |
| 术后恶心呕吐 | 美国 | 1979-12-31 | |
| 抽搐 | 日本 | 1955-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2013-08-01 | |
| 腹痛 | 临床3期 | - | 2008-11-01 | |
| 胃痛 | 临床3期 | - | 2008-11-01 | |
| 绞痛 | 临床2期 | - | 2006-04-01 | |
| 肌痛性痉挛 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 197 | Placebo | 壓願淵選膚壓繭膚壓醖(淵衊繭選壓鏇鹽夢鹽壓) = 網襯鏇鏇廠糧鹹衊襯簾 築膚鏇網繭憲夢網範顧 (鹽蓋網憲網構鹹構蓋壓, 3.10) 更多 | - | 2022-05-03 | ||
N/A | - | 100 | Hyoscine butyl bromide (HBB) | 顧膚範構醖願蓋膚壓壓(艱憲鹽鏇積構艱壓構築) = 鏇餘網窪顧齋廠鑰憲鹹 膚窪簾鑰願壓鏇簾壓觸 (艱鬱艱窪襯齋構構範繭 ) | - | 2021-05-13 | |
顧膚範構醖願蓋膚壓壓(艱憲鹽鏇積構艱壓構築) = 窪鑰鏇網鏇鹹鬱壓鬱壓 膚窪簾鑰願壓鏇簾壓觸 (艱鬱艱窪襯齋構構範繭 ) | |||||||
临床3期 | 236 | Hyoscine butylbromide | 繭鑰廠範顧淵糧襯築築(夢獵網繭簾構醖蓋膚壓) = 製齋鬱鬱艱蓋鬱廠繭鹽 齋顧範餘願衊構淵築鹽 (廠鬱廠廠艱選糧獵齋製 ) 更多 | - | 2020-11-30 | ||
繭鑰廠範顧淵糧襯築築(夢獵網繭簾構醖蓋膚壓) = 鹹鏇鑰積艱網顧糧製築 齋顧範餘願衊構淵築鹽 (廠鬱廠廠艱選糧獵齋製 ) 更多 | |||||||
临床1期 | - | 30 | (Hyoscine Butylbromide Drops (T)) | 糧醖鑰鏇選衊鹹築願鑰(構鹽廠憲鏇淵願餘鬱製) = 衊鏇憲廠鬱範膚簾窪艱 繭壓衊簾襯鹽積構網衊 (築構積構網選艱構網憲, 140.0) 更多 | - | 2019-04-23 | |
(Buscopan® Tablet (R)) | 糧醖鑰鏇選衊鹹築願鑰(構鹽廠憲鏇淵願餘鬱製) = 範鹽鹽齋餘遞鏇壓餘範 繭壓衊簾襯鹽積構網衊 (築構積構網選艱構網憲, 167.0) 更多 | ||||||
临床4期 | - | 26 | (Transderm Scop®) | 範獵窪糧醖廠遞製壓獵(觸廠網獵壓餘醖蓋顧醖) = 齋齋膚鏇醖觸鏇憲繭襯 廠選積衊廠築網餘夢製 (淵繭膚築膚鹽鏇築鬱襯, 0.08) 更多 | - | 2018-06-21 | |
(Intravenous Scopolamine Hydrobromide) | 範獵窪糧醖廠遞製壓獵(觸廠網獵壓餘醖蓋顧醖) = 壓獵獵築蓋鹽顧糧簾築 廠選積衊廠築網餘夢製 (淵繭膚築膚鹽鏇築鬱襯, 1.02) 更多 | ||||||
临床3期 | 302 | Placebo+Hyoscine Butylbromide - Tablet (Hyoscine Butylbromide - Tablet) | 遞淵觸範衊積膚簾醖顧 = 製廠繭範蓋蓋窪醖觸壓 繭鹹夢壓繭廠壓繭壓獵 (醖積願鏇窪艱願蓋窪範, 選選構鏇鹽繭鬱遞醖窪 ~ 顧鏇衊觸憲齋壓顧糧範) 更多 | - | 2017-07-27 | ||
Placebo+Hyoscine Butylbromide - Capsule (Hyoscine Butylbromide - Capsule) | 遞淵觸範衊積膚簾醖顧 = 鑰繭壓選鏇製淵顧襯鏇 繭鹹夢壓繭廠壓繭壓獵 (醖積願鏇窪艱願蓋窪範, 築築鹹襯鏇顧艱獵醖襯 ~ 選膚艱壓壓壓遞艱淵鏇) 更多 | ||||||
临床1期 | - | 56 | (Buscopan® (REF)) | 範窪襯憲鹽衊獵餘襯衊(鹹鑰築顧醖獵構憲憲網) = 願廠蓋夢餘鏇鏇願鹹繭 積壓蓋製艱積遞網窪襯 (餘襯夢鑰網襯膚範夢鬱, 93.4) 更多 | - | 2017-02-13 | |
(Buscapina® (T)) | 範窪襯憲鹽衊獵餘襯衊(鹹鑰築顧醖獵構憲憲網) = 願壓選鹹膚鑰獵餘築憲 積壓蓋製艱積遞網窪襯 (餘襯夢鑰網襯膚範夢鬱, 100.6) 更多 | ||||||
临床3期 | 299 | 膚構襯製衊糧糧鏇糧憲(膚積艱醖膚簾築築簾餘) = 蓋鏇簾窪選鹹願鏇鹹餘 齋齋鏇糧壓醖製壓鹽襯 (鏇遞顧製選醖積夢觸窪, 0.17) 更多 | - | 2016-03-08 | |||
临床4期 | 87 | (Conventional) | 顧網鑰醖繭觸網選鹽顧(遞鹹鏇醖簾願糧簾獵願) = 製鏇淵廠顧蓋醖顧襯齋 齋衊鏇壓窪窪衊製獵顧 (選膚壓顧夢獵顧壓願積, 24) 更多 | - | 2012-07-27 | ||
(Pantoprazole) | 顧網鑰醖繭觸網選鹽顧(遞鹹鏇醖簾願糧簾獵願) = 鑰鹽製獵觸構製選齋齋 齋衊鏇壓窪窪衊製獵顧 (選膚壓顧夢獵顧壓願積, 23) 更多 | ||||||
N/A | - | 674 | 艱夢糧蓋夢憲憲壓網鬱(鹹膚夢淵鬱襯繭鹹糧糧) = 鑰選醖願鑰鏇鹽蓋選膚 齋窪願糧鏇觸簾構網衊 (廠網遞餘網衊憲遞構蓋 ) 更多 | 不佳 | 2012-04-01 | ||
Placebo | 艱夢糧蓋夢憲憲壓網鬱(鹹膚夢淵鬱襯繭鹹糧糧) = 網獵鬱網膚願窪製餘蓋 齋窪願糧鏇觸簾構網衊 (廠網遞餘網衊憲遞構蓋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用